… of the clinical study showed that IL-6 antagonist is effective in patients with COVID-19(3). …
of the IL-6 antagonist on the COVID-19 frontline. According to the treatment guidelines …

… and cytokine release occurring in COVID-19 cases is variable… biological modulators for the
treatment of COVID-19, but the … inflammatory modulator targeting a cytokine storm effect may …

… patients, several drugs are under trials to control the cytokine storm. … management of cytokine
storms in COVID-19 patients. Hitherto, several promising candidates such as IL-1 and IL-6 …

… cytokine release syndrome (CRS) caused by CAR T cell therapy 23 in several aspects. First,
COVID-CS involves more inflammatory cytokines … aggressive nature of COVID-19. Second, …

… Depending on the amount of cytokine production induced by the immunological activation
caused by SARS-CoV-2, three major clinical phenotypes have been identified: mild - …

… COVID-19. While comparisons have been made between COVID-19 cytokine storm and other
kinds of cytokine … and cytokine release syndrome, the pathogenesis of cytokine storm has …

… with coronavirus disease 2019 (COVID‑19) can cause a potentially lethal unconstrained
inflammatory cytokine storm, known as cytokine release … suffering from COVID‑19. Preliminary …

… Given the efficacy of tocilizumab in CRS and the pivotal role of IL-6 in COVID-19, we propose
to repurpose tocilizumab to treat severe cases of COVID-19. Regarding its clinical use, we …

… treatment of the cytokine storm are important components for rescuing patients with severe
COVID-19… and cytokine secretion patterns based on COVID-19 severity are shown in Table 2. …

… coronavirus disease-2019 (COVID-19). This review aimed to discuss current therapeutic
options for the management of CRS in COVID-19. … the COVID-19 infection, the cytokine release …